Antiparkinsonian Action of Phenylisopropylamines

Abstract

A method of treating a subject for Parkinson's disease comprises administering said subject a phenylisopropylamine in an amount effective to treat said Parkinson's disease. In some embodiments the method is used to treat at least a motor symptom of Parkinson's disease; in some embodiments the method is used to treat at least a non-motor symptom of Parkinson's disease.

1 - 23 . (canceled) 
     
     
         24 . A pharmaceutical composition comprising an active compound as described herein in combination with an additional antiparkinson's agent, with the active compound included in an amount effective to reduce the dosage of said antiparkinson's agent, reduce at least one undesired side effect of said antiparkinson's agent, or synergistically enhance the efficacy of said antiparkinson's agent,
 wherein said active agent is a phenylisopropylamine or a pharmaceutically acceptable salt or prodrug thereof.   
     
     
         25 . The composition of  claim 24 , wherein said active compound is a compound of Formula I: 
       
         
           
           
               
               
           
         
       
       wherein:
 R n1 , R n2  and R a  are each independently selected from the group consisting of H, hydroxy, and loweralkyl; 
 R 1  is selected from the group consisting of H, hydroxy and oxo (═O); and 
 R 2 , R 3 , R 4 , R 5  and R 6  are each independently selected from the group consisting of H, halo, loweralkyl, haloalkyl, loweralkoxy, haloloweralkoxy; loweralkylthio, haloloweralkylthio, and nitro; 
 or an adjacent pair of R 2  and R 3 , R 3  and R 4 , or R 4  and R 5  may together form a group of the formula —OCH 2 O—; 
 or a pharmaceutically acceptable salt or prodrug thereof. 
 
     
     
         26 . The composition of  claim 24 , wherein said antiparkinson's agent is selected from the group consisting of amantadine, apomorphine, bromocriptine, levodopa, pergolide, ropinirole, selegiline, trihexyphenidyl, atropine, scopolamine, glycopyrrolate, pharmaceutically acceptable acid addition salts and prodrugs thereof, and combinations thereof. 
     
     
         27 . The composition of  claim 24 , wherein said composition is an oral dosage composition. 
     
     
         28 . A tablet or capsule comprising a composition of  claim 27 . 
     
     
         29 . The tablet or capsule of  claim 28 , wherein said active compound is included in an amount of from 1 to 50 milligrams. 
     
     
         30 . The tablet or capsule of  claim 28 , and wherein said additional antiparkinson's agent is included in an amount of from 0.1 to 200 milligrams. 
     
     
         31 . The tablet or capsule of  claim 28 , wherein said additional antiparkinson's agent is levodopa, and wherein said composition further comprises carbidopa and optionally a COMT inhibitor. 
     
     
         32 . The tablet or capsule of  claim 28 , wherein said additional antiparkinson's agent is a dopamine agonist. 
     
     
         33 . The tablet or capsule of  claim 28 , wherein said additional antiparkinson's agent is an anticholinergic. 
     
     
         34 . The tablet or capsule of  claim 28 , wherein said additional antiparkinson's agent is a monoamine oxidase inhibitor. 
     
     
         35 - 40 . (canceled)